Biodesix

BDSX

Market cap $209M

Biodesix (BDSX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.

Here is how Biodesix, Inc. (BDSX) and BillionToOne (BLLN) have performed compared to their sector so far this year.

BTSG, BDSX and HQY stand to benefit as digital health, healthcare analytics and nursing care growth offset workforce strains.

The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences:

Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals Includes real-world clinical data from Biodesix researchers and independent Healthcare Professionals

The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Biodesix, Inc. (BDSX) Q1 2026 Earnings Call Transcript

Biodesix, Inc. (BDSX) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $1.26. This compares to a loss of $1.6 per share a year ago.

Delivered $25.6 million in revenue representing 42% growth in Q1 2026; Achieved 84% gross margin in Q1 2026; Increased FY 2026 Revenue Guidance to $108-114 million, mid-point reflects 25% growth; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo.